
FUTURE PLANS AND USE OF [REDACTED]

FUTURE PLANS

For details of our future plans, see “Business—Our Strategies.”

USE OF [REDACTED]

We estimate that we will receive net [REDACTED] of approximately HK\$[REDACTED] after deducting the [REDACTED] fees and expenses payable by us in the [REDACTED], assuming no exercise of the [REDACTED] and assuming an [REDACTED] of HK\$[REDACTED] per [REDACTED], being the mid-point of the indicative [REDACTED] range of HK\$[REDACTED] to HK\$[REDACTED] per [REDACTED] in this document.

We intend to use the net [REDACTED] from the [REDACTED] for the following purposes:

- Approximately HK\$[REDACTED] (representing [REDACTED]% of the net [REDACTED]) will be used for OT-401, our Core Product, as follows:
 - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to fund the continuing research and development activities of OT-401, including the ongoing clinical trial and the preparation of registration filings;
 - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for milestone payments of OT-401; and
 - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for the commercialization of OT-401.
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for our other drug candidates:
 - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to fund the continuing research and development activities of the other drug candidates in our pipeline, including the planned clinical trials and the preparation of registration filings;
 - Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to fund the continuing research and development activities of late-stage and near late-stage drug candidates, including OT-101, OT-301, and OT-1001;
 - Approximately HK\$[REDACTED] (representing [REDACTED]% of the net [REDACTED]) will be used to fund the continuing research and development activities of near clinical-stage drug candidates, including OT-502, OT-202, OT-503, and OT-701; and

FUTURE PLANS AND USE OF [REDACTED]

- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used to fund the continuing research and development activities of other drug candidates in different stages.
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for milestone payments of our other in-licensed drug candidates; and
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for the further expansion of our sales and marketing team in anticipation of new product launches in the coming years.
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for the acquisition of the manufacturing facility in Suzhou pursuant to our cooperation agreement with the local government. See “History, Restructuring and Corporate Structure—Major Acquisitions, Disposals and Mergers” and “Waivers from Compliance with the Listing Rules and Exemption from the Companies (Winding Up and Miscellaneous Provisions) Ordinance—Waiver and Exemption in Respect of Accounting and Disclosure Requirements for Acquisitions of Subsidiaries and Businesses Conducted after the Track Record Period” for more details.
- Approximately HK\$[REDACTED] (representing [REDACTED] of the net [REDACTED]) will be used for our working capital and other general corporate purposes.

The above allocation of the [REDACTED] will be adjusted on a *pro rata* basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the estimated [REDACTED] range. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the high end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will increase by approximately HK\$[REDACTED]. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the low end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will decrease by approximately HK\$[REDACTED].

If the [REDACTED] is exercised in full, and net [REDACTED] that we will receive will be approximately HK\$[REDACTED], assuming an [REDACTED] of HK\$[REDACTED] per Share (being the mid-point of the indicative [REDACTED] range). In the event that the [REDACTED] is exercised in full, we intend to apply the additional net [REDACTED] to the above purpose in the proportions stated above.

To the extent that the net [REDACTED] are not immediately applied to the above purposes and to the extent permitted by the relevant law and regulations, so long as it is deemed to be in the best interests of the Company, we may hold such funds in short-term deposits or low-risk and short-term wealth management products offered by reputable commercial banks or reputable financial institutions until such funds are used for the above purposes. We will make an appropriate announcement if there is any change to the above proposed use of [REDACTED].